Showing 431-440 of 8858 results for "".
New Findings Raise Questions About EHRs Going Forward
https://practicaldermatology.com/topics/practice-management/new-findings-raise-questions-about-ehrs-going-forward/22934/A recently published study dampens expectations for the future of EHRs, which may also signal diminished public support.Research Update: Sunscreen Accumulation and Thickness Influence UV Protection
https://practicaldermatology.com/topics/general-topics/study-sunscreen-accumulation-and-thickness-influence-uv-protection/21639/Researchers show specific elements related to sunscreen application affect efficacy.Take 5: Recent Findings in Acne Research
https://practicaldermatology.com/columns/take-5/take-5-recent-findings-in-acne-research/21733/Five new studies examine potentially useful therapies and strategies to improve adherence.Coding Checklist: It's Time to Update Policies and Procedures
https://practicaldermatology.com/topics/general-topics/its-time-to-update-policies-and-procedures/21865/The new year is a good time to establish new policies, including increased collection of patient responsibility for payment.Lead Psoriasis Patients Along the Path to Clearance
https://practicaldermatology.com/topics/psoriasis/PD0209_01-php/22873/With so many effective therapies now available, dermatologists must be prepared to guide their patients to the right treatment for their specific presentation.Derm Residency 2.0; AADA Legislative Conference; Call for Cases
https://practicaldermatology.com/youngmd-connect/resident-resource-center/derm-residency-20-aada-legislative-conference-call-for-cases/20949/BrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-brightguard-covers-nyc-galderma-uncovers-rosacea-burden-dermira-s-qbrexza-approved/18288/BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify theAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaAAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JA